WO2003074060A2 - Combinaison chimiothérapie et antisens de la dna déméthylase - Google Patents
Combinaison chimiothérapie et antisens de la dna déméthylase Download PDFInfo
- Publication number
- WO2003074060A2 WO2003074060A2 PCT/FR2003/000705 FR0300705W WO03074060A2 WO 2003074060 A2 WO2003074060 A2 WO 2003074060A2 FR 0300705 W FR0300705 W FR 0300705W WO 03074060 A2 WO03074060 A2 WO 03074060A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- combination product
- product according
- demethylase
- antisense
- mbd2
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/14—Peptides containing saccharide radicals; Derivatives thereof, e.g. bleomycin, phleomycin, muramylpeptides or vancomycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Definitions
- the present invention relates to a combination product comprising an antisense of the gene coding for demethylase MBD2 and at least one agent used in antitumor chemotherapy, in particular bleomycin, for simultaneous, separate or spread over time use for the treatment of proliferative and inflammatory diseases, in particular for the treatment of cancer.
- DNA methylation is an important epigenetic mechanism that regulates gene expression (1-4).
- One of the characteristics of cancer cells is an aberrant pattern of methylation (5).
- Two contradictory changes in the methylation scheme have been previously documented, namely hypermethylation of selected genes (6) and global hypomethylation (7).
- the DNA methylation machinery consists of DNA methyltransferase (9), demethylases (10), (11) and (12), and methylated DNA binding proteins (MBD) which interpret the signal DNA methylation (13).
- MBD methylated DNA binding proteins
- Methylated cytosines are specifically recognized by MBDs (13) and (19-21), which associate with co-depressants such as Sin3A, recruit histone deacetylases for methylated genes (22-26) and can be found in known transcription repression complexes, such as Mi2 (27).
- Mecp2 which is the best characterized member of the family, is probably not very important in silencing genes during transformation, as it is not expressed in cancer cells (20). Other candidate proteins must be brought into play.
- a recently characterized methylated DNA binding protein, MBD2 is an interesting candidate for the reasons explained below.
- MBD2 cDNA was cloned from a cancer cell line cDNA library (28), and has been shown to be expressed in samples and lines breast cancer cells (29).
- the protein is involved not only in gene suppression by a mechanism analogous to that presented for Mecp2 (24) and (27), but it has also been found to also carry demethylase activity ( 28).
- Demethylase activity has previously been purified from a non-small human lung cancer cell line A549 (12), and so has transfection of the PI embryo cell line 9 by the proto-oncogenic Ha-Ras leads to an increase in demethylase activity (30). It is not impossible that an increased demethylase activity is associated with tumorigenesis, and that it could be partly responsible for the overall hypomethylation observed in cancer cells (17). Thus, Mbd2 / demethylase could be part of the machinery involved in mediating or interpreting the two contradictory changes associated with the DNA methylation scheme in cancer cells, namely hypermethylation and hypomethylation.
- Mbd2b / demethylase obtained by recombination expressed in a heterologous SF-9 cell line, exhibits demethylase activity.
- the co-transfection of Mbd2b / demethylase and methylated plasmids causes demethylation of these plasmids and the forced expression of Mbd2b / demethylase in PANC-1 cells leads to demethylation and induction of the endogenous promoter MUC-2.
- the present invention provides the elements demonstrating that Mbd2 / demethylase is effectively expressed in cancer cells, and that it is essential for the growth of tumor cells in culture and in vivo.
- the main advantage of the invention is therefore its surprising effectiveness, since, if we consider the complete cure rate for tumors, it is 10% using genotherapy by electrotransfer of the MBD2 demethylase gene alone, and also 10% with bleomycin chemotherapy alone, and this rate rises to 40% using the combination of the two treatments: geno- and chemotherapy.
- the present invention relates to a combination product comprising at least one antisense oligonucleotide of the gene coding for demethylase MBD2 and at least one agent used in antitumor chemotherapy for simultaneous, separate or spread over time use intended for the treatment of diseases proliferative and inflammatory.
- the antisense of the gene coding for demethylase MBD2 comprises at least 15 consecutive nucleotides of the sequence SEQ ID No. 1 or of its complementary sequence or of SEQ ID No. 2.
- SEQ ID NO 1 corresponds to the sequence described in GENEBANK under accession number AF 072242 (Homo sapiens methyl-CpG binding protein MBD2 (MBD2) mRNA, complete cds).
- sequence SEQ ID No. 2 which corresponds to the whole messenger RNA of demethylase in the antisense orientation: cgcatgcatgcataagcttgctcgagtctagaltttUltUUUtgtctgtgaatataatcarttatttgtctttacagtgatgatggaa gaatgtacaggtgtccccttttcaataaagtataaaaatatgtttatatacagtgaagtcacaataatcrttaactgggaaatitatttt agaattcctgatctgttcttattaaaactgtgggggaaacaaatgtttttacgtaagtgctacatttccagtagattgcacctggcat caaaagcttcatcttagggtc
- the invention relates to a combination product as mentioned above in which the antisense comprises at least: a) 15 consecutive nucleotides of the sequence SEQ ID No 1 or of its complementary sequence or of the sequence SEQ ID No 2, or b) a sequence capable of hybridizing selectively to one of the sequences defined in a).
- sequence capable of hybridizing selectively is meant the sequences which hybridize with the sequences mentioned above at a level significantly above the background noise.
- the background noise can be linked to the hybridization of other DNA sequences present, in particular other mRNAs present in the targeted tumor cells.
- the level of the signal generated by the interaction between the sequence capable of selective hybridization and the sequences defined by SEQ ID NO 1 to 2 above is generally 10 times, preferably 100 times more intense than that of l interaction of other DNA sequences generating background noise.
- the level of interaction can be measured, for example, by labeling the sequence used as a probe with radioactive elements, such as 32 P.
- Hybridization is generally obtained by using very harsh environmental conditions (for example NaCl 0, 03 M and 0.03 M sodium citrate at about 50 ° C-60 ° C). Hybridization can be carried out according to the usual methods of the prior art (in particular Sambrook & al., 1989, Molecular Cloning: A Labratory Manual).
- an “agent used in antitumor chemotherapy” one intends to designate antineoplastic agents. Among these agents, we can cite:
- cytolytics such as dacarbazine, hydroxycarbamide, Pasparaginase, mitoguazone and plicamycin
- methylating agents such as streptozotocin (2-deoxy-2- (3-methyl-3 nitrosoureido) -D-glucopyranose), procarbazine (N- (l-methylethyl) -4 - [(2- methylhydrazino) methyl] benzamide), dacarbazine or DTIC (5- (3,3-dimethyl-l-triazenyl) -lH-imidazole-4-carboxamide), and Temozolomide (8-carbamoyl-3-methylimidazo [5.1 -d] - 1,2,3,5-tetrazin-4- (3H) -one).
- chloroethylating agents such as HECNU (l- (2-chloroethyl) -3- (2- hydroxyethyl) -l-nitrosourea), BCNU (l, 3-bis (2-chloroethyl) -l-nitrosourea or carmustine, Bristol -Myers), ACNU (l- (2-chloroethyl) -3- (4-amino-2-methyl-5-pyrimidinyl) methyl-l-nitrosourea), CCNU (l- (2-chloroethyl) -3-cyclohexyl- l- nitrosourea or lomustine), MeCCNU (- (2-chloroethyl) -3- (4- methylcyclohexyl) -l-nitrosourea or semustine), fotemustine (l- [N- (2- chloroethyl) -N-nitrosoureido] ethylphosphonic acid
- pro-apoptotic agents selected from glucocorticoid derivatives, topoisomerase inhibitors such as topoisomerase 2 inhibitors, for example anthracyclines, epipodophyllotoxin such as etoposide, topoisomerase 1 inhibitors, for example camptothecin derivatives,
- antifolates for example methotrexate
- antipurines for example 6-mercaptopurine
- antipyrimides for example 5-fluorouracil
- antimitotics such as vinca alkaloids, taxoids such as taxotere,
- the invention relates to a combination product as defined above, in which the agent is selected from compounds belonging to the bleomycin family, in particular bleomycin.
- the invention relates to a combination product mentioned above, in which the antisense oligonucleotide of the gene coding for demethylase MBD2 is carried by a vector comprising a promoter allowing its efficient expression in a cell eukaryote.
- This vector may also include a poly A transcription termination sequence.
- the vector consists of a plasmid.
- the use of a plasmid is more economical and safer than the use of viruses.
- this embodiment of the invention allows re-administration without triggering an immune response.
- This plasmid advantageously comprises a promoter, the antisense sequence according to the invention and a transcription terminator sequence.
- the antisense sequence is inserted into the plasmid pcDNA3.1HisA from the company InVitrogen.
- the product according to the invention may also comprise one or more pharmaceutically acceptable vehicle (s). It is intended in particular for simultaneous, separate or spread over time intended for the treatment of cancer. In this sense, in a preferred mode, the formulations are suitable for administration by intratumoral injection.
- AD ⁇ is associated with compounds intended to promote its transfection, such as proteins, liposomes, charged lipids or cationic polymers such as polyethylenimine, which are good agents for in vitro transfection (Behr et al. Proc. ⁇ atl. Acad. Sci. USA 86, 6982-6, 1989; Felgner et al. Proc. ⁇ atl. Acad. Sci. USA 84, 7413-7, 1987; Boussif et al. Proc. Latl. Acad. Sci. USA 92, 7297-301, 1995).
- compounds intended to promote its transfection such as proteins, liposomes, charged lipids or cationic polymers such as polyethylenimine
- the antisense can also be transferred in the form of double-stranded DNA or of a plasmid as mentioned above in combination or not with a molecule promoting transfer and / or by using a weak electric field.
- the invention also extends to any application making it possible to treat cancer, comprising the use of a combination product mentioned above and a third active substance used in the context of the treatment of cancer.
- the invention covers tri-therapy comprising the administration of the combination product according to the invention and a third active substance.
- Mbd2 / demethylase is expressed in tumors in vivo and is overexpressed in a significant percentage of tumor in a manner analogous to Dmntl. While our analysis of a limited number of tumors does not prove that Mbd2 / demethylase is generally deregulated in cancer cells, our data are compatible with this model.
- Mbd2 / demethylase can either repress or demethylate methylated genes, it is possible that a number of genes are affected by either of these processes.
- the inhibition of the repression, mediated by Mbd2 / demethylase, of the activity of methylated genes could result in the activation of a certain number of tumor suppressors.
- demethylase activity may be required to inhibit aberrant methylation of genes that are critical for the transformed phenotype. Inhibition of demethylase could lead to ectopic methylation, with critical genes being silenced in a stochastic manner.
- the inhibition of Mbd2 / demethylase results in repression and in an induction of the expression of the genes involved in the tumor process, but does not present any disadvantage for a therapeutic application.
- Changes in gene expression after treatment with the Mbd2 / demethylase antisense appear to be limited, but these changes, reinforced by an alkylating agent, are responsible for the strong inhibition of tumorigenesis in vitro.
- the invention proposes to use Mbd2 / demethylase jointly as an anti-cancer target and a DNA alkylating agent.
- Mbd2 / demethylase jointly as an anti-cancer target and a DNA alkylating agent.
- the inhibition of Mbd2 / demethylase could have a therapeutic effect on two levels, one in restoring the normal state of genomic methylation by inhibition of an aberrantly overregulated demethylase, and another, which prevents that become silent poorly methylated tumor suppressor genes, which are essential for maintaining proper regulation of cell growth.
- Example 1 Combination of gene therapy (intratumoral electrotransfer of plasmids coding for the DNA Demethylase antisense) and chemotherapy (intramuscular injection of bleomycin)
- mice Two series of experiments were carried out in the nude mouse weighing 18 to 20 g.
- the mice were implanted mono-laterally with grafts of H 1299 tumors (non-small cell human lung tumors) of approximately 20 mm 3.
- the tumors have grown to reach a volume of 20 to 150mm3.
- the mice were anesthetized with a Ketamine, Xylazine mixture.
- Control tumors a series of tumors did not undergo any treatment.
- the plasmid solution was injected longitudinally at the periphery of the tumor using a Hamilton syringe.
- the lateral faces of the tumors were coated with conductive gel and the tumors were placed between 2 flat stainless steel electrodes 0.4 to 0.7 cm apart.
- the plasmids were electrotransfered using a commercial (square) electric pulse generator (PS 15 Jouan electropulser). Each tumor was subjected to 500V / cm delivered in 8 pulses with a duration of 20 msec at a frequency of 1 Hertz.
- the tumor volumes were measured individually for each tumor using an electronic caliper with digital display according to the formula (length X width X thickness) / 2.
- the median of tumor volumes has been plotted as a function of time.
- Tumors treated with bleomycin alone Twenty five ⁇ g of bleomycin / animal in 50 ⁇ L of 150 mM NaCl were injected bilaterally into the tibialis cranialis muscle and 30 minutes later, each tumor was injected with 80 ⁇ l of 150 mM NaCL and subjected to an electrotransfer. Four other electrotransferts of 80 ⁇ L 150 mM NaCl were then carried out in the tumors on the days indicated by the arrows.
- Tumors treated with a combination of the 2 treatments Twenty five ⁇ g of bleomycin / animal in 50 ⁇ L of 150 mM NaCl were injected bilaterally into the tibialis cranialis muscle and 30 minutes later, an electrotransfer of 50 ⁇ g of plasmid antisense in 80 ⁇ L 150mM NaCl was produced. Four other electrotransfer of 50 ⁇ g of antisense plasmid in 80 ⁇ L 150 mM NaCl were then carried out in the tumors on the days indicated by the arrows.
- the tumor volumes were measured individually for each tumor using an electronic caliper with digital display according to the formula (length X width X thickness) / 2.
- the median of tumor volumes has been plotted as a function of time.
- cured tumors are tumors that are no longer measurable
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- General Chemical & Material Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Molecular Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Gastroenterology & Hepatology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Description
Claims
Priority Applications (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP03727568A EP1480655A2 (fr) | 2002-03-07 | 2003-03-05 | Combinaison chimioththerapie et antisens de la dna demethylase |
US10/506,766 US20060009403A1 (en) | 2002-03-07 | 2003-03-05 | Dna demethylase antisense and chemotherapy combination |
CA002478124A CA2478124A1 (fr) | 2002-03-07 | 2003-03-05 | Combinaison chimiotherapie et antisens de la dna demethylase |
AU2003233360A AU2003233360A1 (en) | 2002-03-07 | 2003-03-05 | Dna demethylase antisense and chemotherapy combination |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR0202879A FR2836831B1 (fr) | 2002-03-07 | 2002-03-07 | Combinaison chimiotherapie et antisens de la dna demethylase |
FR02/02879 | 2002-03-07 |
Publications (3)
Publication Number | Publication Date |
---|---|
WO2003074060A2 true WO2003074060A2 (fr) | 2003-09-12 |
WO2003074060A3 WO2003074060A3 (fr) | 2004-04-08 |
WO2003074060A8 WO2003074060A8 (fr) | 2004-06-10 |
Family
ID=27763612
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/FR2003/000705 WO2003074060A2 (fr) | 2002-03-07 | 2003-03-05 | Combinaison chimiothérapie et antisens de la dna déméthylase |
Country Status (6)
Country | Link |
---|---|
US (1) | US20060009403A1 (fr) |
EP (1) | EP1480655A2 (fr) |
AU (1) | AU2003233360A1 (fr) |
CA (1) | CA2478124A1 (fr) |
FR (1) | FR2836831B1 (fr) |
WO (1) | WO2003074060A2 (fr) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2004001027A1 (fr) * | 2002-06-20 | 2003-12-31 | Mcgill University | Inhibiteurs oligonucleotidiques de mbd2/adn demethylase et utilisations correspondantes |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR3121039B1 (fr) * | 2021-03-25 | 2023-03-31 | Univ Grenoble Alpes | Oligonucléotides anti-sens pour leur utilisation dans un traitement anticancéreux |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1997039135A1 (fr) * | 1996-04-17 | 1997-10-23 | Board Of Regents, The University Of Texas System | Expression renforcee de transgenes |
WO1999001157A1 (fr) * | 1997-06-30 | 1999-01-14 | Rhone-Poulenc Rorer S.A. | Amelioration du transfert d'acide nucleique dans les cellules d'organismes eucaryotes pluricellulaires et combinaison permettant la mise en oeuvre du procede |
WO1999024583A1 (fr) * | 1997-11-12 | 1999-05-20 | Mcgill University | Adn demethylase, utilisations therapeutiques et diagnostiques de celle-ci |
Family Cites Families (81)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2709785A (en) * | 1951-05-03 | 1955-05-31 | Robertshaw Fulton Controls Co | Measurement of conductivity of liquids |
US3433935A (en) * | 1963-07-12 | 1969-03-18 | Herbert Sherman | Apparatus for computation particularly adapted for producing a measure of transit time and the like |
US3324720A (en) * | 1963-07-29 | 1967-06-13 | Friends Of Psychiatric Res Inc | Apparatus and method for determining rate of flow by measurement of electrical property of stream |
US3404336A (en) * | 1965-07-26 | 1968-10-01 | Beckman Instruments Inc | Apparatus for measuring electrical conductivity of a fluid |
FR1452215A (fr) * | 1965-07-28 | 1966-09-09 | Philips Massiot Mat Medic | Dispositif pour mesurer le débit d'un fluide |
US3396331A (en) * | 1965-08-19 | 1968-08-06 | Beckman Instruments Inc | Method of and apparatus for measuring the electrical conductivity of a solution |
US3450984A (en) * | 1965-10-21 | 1969-06-17 | Avco Corp | Method and apparatus for measuring the flow velocity of an electrolytic fluid by electrolysis |
US3482575A (en) * | 1967-02-16 | 1969-12-09 | Single Cell Research Foundatio | Method for the extracorporeal oxygenation of blood |
US3561266A (en) * | 1967-07-10 | 1971-02-09 | Philips Corp | Device for measuring the flow velocity of a fluid |
US3491592A (en) * | 1967-10-23 | 1970-01-27 | Nalco Chemical Co | Measurement of flow rate of aqueous streams |
JPS5149223B1 (fr) * | 1968-01-31 | 1976-12-25 | ||
US3545428A (en) * | 1968-10-10 | 1970-12-08 | Wilton W Webster Jr | Massflowmeter catheter |
US3640271A (en) * | 1969-06-30 | 1972-02-08 | Ibm | Blood flow pressure measurement technique employing injected bubbled and ultrasonic frequency scanning |
US3619423A (en) * | 1970-04-20 | 1971-11-09 | Us Health Education & Welfare | Cascade dialysis apparatus and method |
DE2123134C3 (de) * | 1970-05-25 | 1979-03-01 | N.V. Philips' Gloeilampenfabrieken, Eindhoven (Niederlande) | Verfahren zum Messen der Strömungsstarke |
US4153418A (en) * | 1971-05-10 | 1979-05-08 | Haas Rudy M | Chemical tracer method of and structure for determination of instantaneous and total mass and volume fluid flow |
US3722276A (en) * | 1971-12-06 | 1973-03-27 | Tetradyne Corp | Volumetric flow rate measurement of a flowing stream |
US4167870A (en) * | 1973-09-07 | 1979-09-18 | Haas Rudy M | Chemical tracer method of and structure for determination of instantaneous and total mass and volume fluid flow |
NL158390B (nl) * | 1973-11-26 | 1978-11-15 | Rhone Poulenc Sa | Inrichting voor buitenlichamelijke bloedkringloop voor dialyse. |
US3867688A (en) * | 1973-12-18 | 1975-02-18 | Atomic Energy Commission | Electrodeless conductance measurement device |
FR2266891B1 (fr) * | 1974-04-05 | 1978-11-17 | Citroen Sa | |
US3964479A (en) * | 1974-11-20 | 1976-06-22 | Cobe Laboratories, Inc. | Extracorporeal blood circulation system and drip chamber with adjustable blood level |
US3987788A (en) * | 1975-07-09 | 1976-10-26 | American Hospital Supply Corporation | System for computing cardiac flow rates from thermodilution measurements |
JPS5911864B2 (ja) * | 1975-07-14 | 1984-03-19 | 武田薬品工業株式会社 | 漏血検知装置 |
US4081372A (en) * | 1975-12-08 | 1978-03-28 | University Of Utah | Leakage indicator for recirculating peritoneal dialysis system |
US4138639A (en) * | 1977-07-14 | 1979-02-06 | Hutchins Thomas B | Fluid conductivity measurement |
US4136563A (en) * | 1977-09-30 | 1979-01-30 | Tetradyne Corporation | Digital volumetric flow rate measurement of a flowing fluid |
JPS56104646A (en) * | 1980-01-25 | 1981-08-20 | Minolta Camera Kk | Optical analyzer for forming ratio of element contained in organism |
US4361049A (en) * | 1980-08-18 | 1982-11-30 | The Hospital For Sick Children | Apparatus for calculating cardiac output |
US4391124A (en) * | 1981-02-26 | 1983-07-05 | Cornell Research Foundation, Inc. | Electroacoustic transducer calibration method and apparatus |
US4434648A (en) * | 1981-02-26 | 1984-03-06 | Cornell Research Foundation, Inc. | Electroacoustic transducer calibration method and apparatus |
DE3223051C2 (de) * | 1982-06-21 | 1984-09-13 | Fresenius AG, 6380 Bad Homburg | Dialysevorrichtung mit geregelter Dialysierlösung |
US4432231A (en) * | 1982-06-28 | 1984-02-21 | Baxter Travenol Laboratories, Inc. | Ultrasonic level detector |
US4856321A (en) * | 1983-07-29 | 1989-08-15 | Panametrics, Inc. | Apparatus and methods for measuring fluid flow parameters |
SE458340B (sv) * | 1984-06-18 | 1989-03-20 | Gambro Lundia Ab | Blodfiltreringssystem samt dropp- och /eller expansionskammare avsedd foer detta system |
US4747822A (en) * | 1984-07-09 | 1988-05-31 | Peabody Alan M | Continuous flow peritoneal dialysis system and method |
US4739492A (en) * | 1985-02-21 | 1988-04-19 | Cochran Michael J | Dialysis machine which verifies operating parameters |
JPS61196963A (ja) * | 1985-02-26 | 1986-09-01 | 株式会社クラレ | 脱血補助装置 |
US4777958A (en) * | 1985-10-28 | 1988-10-18 | Board Of Regents, The University Of Texas System | Method for enhancing the accuracy of in vivo sound velocity estimation |
SE459641B (sv) * | 1986-03-24 | 1989-07-24 | Gambro Ab | Detektorsystem foer kontroll av en foer ledning av blod alternerande med en vaesentligen faergloes vaetska avsedd vaetskeslang |
US4825168A (en) * | 1986-05-30 | 1989-04-25 | Cobe Laboratories, Inc. | Remote conductivity sensor using square wave excitation |
US4740755A (en) * | 1986-05-30 | 1988-04-26 | Cobe Laboratories, Inc. | Remote conductivity sensor having transformer coupling in fluid flow path |
DE3620873A1 (de) * | 1986-06-21 | 1987-12-23 | Rau Guenter | Vorrichtung zur bestimmung des partialdruckes von in einem fluid geloesten gasen und gasgemischen |
US4885087A (en) * | 1986-11-26 | 1989-12-05 | Kopf Henry B | Apparatus for mass transfer involving biological/pharmaceutical media |
DE3720665A1 (de) * | 1987-06-23 | 1989-01-05 | Schael Wilfried | Vorrichtung zur haemodialyse und haemofiltration |
US4822341A (en) * | 1987-11-20 | 1989-04-18 | Impra, Inc. | Vascular access fistula |
SE465404B (sv) * | 1988-03-03 | 1991-09-09 | Gambro Ab | Dialyssystem |
US4885001A (en) * | 1988-06-03 | 1989-12-05 | Cobe Laboratories, Inc. | Pump with plural flow lines |
US5230341A (en) * | 1988-08-13 | 1993-07-27 | Fresenius Ag | Measuring the change of intravascular blood volume during blood filtration |
DE3909967A1 (de) * | 1989-03-25 | 1990-09-27 | Fresenius Ag | Haemodialysegeraet mit automatischer einstellung des dialysierfluessigkeitsflusses |
DE3923836C1 (fr) * | 1989-07-19 | 1990-09-20 | Fresenius Ag, 6380 Bad Homburg, De | |
US4995268A (en) * | 1989-09-01 | 1991-02-26 | Ash Medical System, Incorporated | Method and apparatus for determining a rate of flow of blood for an extracorporeal blood therapy instrument |
DE3938662A1 (de) * | 1989-11-21 | 1991-07-18 | Fresenius Ag | Verfahren zur in-vivo-bestimmung von parametern der haemodialyse |
US5372136A (en) * | 1990-10-06 | 1994-12-13 | Noninvasive Medical Technology Corporation | System and method for noninvasive hematocrit monitoring |
US5644240A (en) * | 1992-09-30 | 1997-07-01 | Cobe Laboratories, Inc. | Differential conductivity hemodynamic monitor |
EP0835669A3 (fr) * | 1992-09-30 | 1998-09-09 | COBE Laboratories, Inc. | ContrÔleur de recirculation différentiel |
KR100318579B1 (ko) * | 1992-10-13 | 2002-06-20 | 데이비드 씨. 맥키, 토마스 제어. 시바티노 | 혈액투석기용혈액투석모니터시스템 |
WO1994009351A1 (fr) * | 1992-10-13 | 1994-04-28 | Baxter International Inc. | Module d'echantillonnage de fluides |
US6001563A (en) * | 1992-10-27 | 1999-12-14 | Queen's University At Kingston | Methods for identifying chemosensitizers |
US5357967A (en) * | 1993-06-04 | 1994-10-25 | Baxter International Inc. | Method and apparatus for measuring flow using frequency-dispersive techniques |
US5685988A (en) * | 1993-09-15 | 1997-11-11 | Malchesky; Paul | Dialysis process and system |
US5507723A (en) * | 1994-05-24 | 1996-04-16 | Baxter International, Inc. | Method and system for optimizing dialysis clearance |
US5588959A (en) * | 1994-08-09 | 1996-12-31 | University Of Washington | Hemodialysis recirculation measuring method |
US6153109A (en) * | 1994-09-16 | 2000-11-28 | Transonic Systmes, Inc. | Method and apparatus to measure blood flow rate in hemodialysis shunts |
US6514419B2 (en) * | 1994-09-16 | 2003-02-04 | Transonic Systems, Inc. | Method to measure blood flow and recirculation in hemodialysis shunts |
DE19528907C1 (de) * | 1995-08-05 | 1996-11-07 | Fresenius Ag | Vorrichtung zur Ermittlung hämodynamischer Parameter während einer extrakorporalen Blutbehandlung |
SE508374C2 (sv) * | 1995-09-12 | 1998-09-28 | Gambro Med Tech Ab | Förfarande och anordning för detektering av tillståndet hos en blodkärlsaccess |
DE19541783C1 (de) * | 1995-11-09 | 1997-03-27 | Fresenius Ag | Verfahren zum Betreiben einer Blutbehandlungsvorrichtung zur Ermittlung hämodynamischer Parameter während einer extrakorporalen Blutbehandlung und Vorrichtung zur Ermittlung hämodynamischer Parameter während einer extrakorporalen Blutbehandlung |
SE9602298D0 (sv) * | 1996-06-11 | 1996-06-11 | Siemens Elema Ab | Arrangement for analysing body fluids |
US6117099A (en) * | 1996-10-23 | 2000-09-12 | In-Line Diagnostics Corporation | System and method for noninvasive hemodynamic measurements in hemodialysis shunts |
US6061590A (en) * | 1997-06-03 | 2000-05-09 | Transonic Systems, Inc. | Method and apparatus for predicting intradialytic morbid events through the monitoring of a central blood volume |
US6189388B1 (en) * | 1997-11-12 | 2001-02-20 | Gambro, Inc. | Access flow monitoring using reversal of normal blood flow |
US6177049B1 (en) * | 1998-06-10 | 2001-01-23 | Dsu Medical Corporation | Reversing flow blood processing system |
DE19848235C1 (de) * | 1998-10-20 | 2000-03-16 | Fresenius Medical Care De Gmbh | Verfahren zur Überwachung eines Gefäßzuganges und Vorrichtung zur extrakorporalen Blutbehandlung mit einer Einrichtung zur Überwachung des Gefäßzuganges |
US6008048A (en) * | 1998-12-04 | 1999-12-28 | Isis Pharmaceuticals Inc. | Antisense inhibition of EGR-1 expression |
DE19901078C1 (de) * | 1999-01-14 | 2000-02-17 | Polaschegg Hans Dietrich | Verfahren und Vorrichtung zur Erkennung von Stenosen bei der extrakorporalen Blutbehandlung |
US6319465B1 (en) * | 1999-06-03 | 2001-11-20 | Dsu Medical Corporation | Reversing flow blood processing system having reduced clotting potential |
AU1928801A (en) * | 1999-11-24 | 2001-06-04 | Curagen Corporation | Nucleic acids containing single nucleotide polymorphisms and methods of use thereof |
US6308737B1 (en) * | 2000-03-10 | 2001-10-30 | Transonic Systems, Inc. | Method and apparatus for selectively reversing flow between a dialyzer and a patient access |
IL154129A0 (en) * | 2000-07-28 | 2003-07-31 | Compugen Inc | Oligonucleotide library for detecting rna transcripts and splice variants that populate a transcriptome |
AU2003243859A1 (en) * | 2002-06-20 | 2004-01-06 | Mcgill University | Oligonucleotide inhibitors of mbd2/dna demethylase and uses thereof |
-
2002
- 2002-03-07 FR FR0202879A patent/FR2836831B1/fr not_active Expired - Fee Related
-
2003
- 2003-03-05 US US10/506,766 patent/US20060009403A1/en not_active Abandoned
- 2003-03-05 EP EP03727568A patent/EP1480655A2/fr not_active Withdrawn
- 2003-03-05 CA CA002478124A patent/CA2478124A1/fr not_active Abandoned
- 2003-03-05 WO PCT/FR2003/000705 patent/WO2003074060A2/fr not_active Application Discontinuation
- 2003-03-05 AU AU2003233360A patent/AU2003233360A1/en not_active Abandoned
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1997039135A1 (fr) * | 1996-04-17 | 1997-10-23 | Board Of Regents, The University Of Texas System | Expression renforcee de transgenes |
WO1999001157A1 (fr) * | 1997-06-30 | 1999-01-14 | Rhone-Poulenc Rorer S.A. | Amelioration du transfert d'acide nucleique dans les cellules d'organismes eucaryotes pluricellulaires et combinaison permettant la mise en oeuvre du procede |
WO1999024583A1 (fr) * | 1997-11-12 | 1999-05-20 | Mcgill University | Adn demethylase, utilisations therapeutiques et diagnostiques de celle-ci |
Non-Patent Citations (4)
Title |
---|
BHATTTACHARYA SK ET AL: "A mammalian protein with specific demethylase activity for mCpG DNA" NATURE, vol. 397, 18 février 1999 (1999-02-18), pages 579-583, XP002097746 ISSN: 0028-0836 cité dans la demande * |
IVANOV MARIE-AGNÈS ET AL: "Enhanced antitumor activity of a combination of MBD2-antisense electrotransfer gene therapy and bleomycin electrochemotherapy." THE JOURNAL OF GENE MEDICINE, vol. 5, no. 10, octobre 2003 (2003-10), pages 893-899, XP002258943 ISSN: 1099-498X * |
SLACK ANDREW ET AL: "Antisense MBD2 gene therapy inhibits tumorigenesis." THE JOURNAL OF GENE MEDICINE, vol. 4, no. 4, 17 mai 2002 (2002-05-17), pages 381-389, XP008009438 ISSN: 1099-498X * |
SZYF MOSHE: "The DNA methylation machinery as a therapeutic target." CURRENT DRUG TARGETS, vol. 1, no. 1, juillet 2000 (2000-07), pages 101-118, XP001122812 ISSN: 1389-4501 * |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2004001027A1 (fr) * | 2002-06-20 | 2003-12-31 | Mcgill University | Inhibiteurs oligonucleotidiques de mbd2/adn demethylase et utilisations correspondantes |
Also Published As
Publication number | Publication date |
---|---|
AU2003233360A8 (en) | 2003-09-16 |
AU2003233360A1 (en) | 2003-09-16 |
EP1480655A2 (fr) | 2004-12-01 |
FR2836831B1 (fr) | 2004-06-25 |
US20060009403A1 (en) | 2006-01-12 |
FR2836831A1 (fr) | 2003-09-12 |
WO2003074060A8 (fr) | 2004-06-10 |
CA2478124A1 (fr) | 2003-09-12 |
WO2003074060A3 (fr) | 2004-04-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN108138181B (zh) | 抑制黑色素生成的rna复合物 | |
EP2102343B1 (fr) | Dbait et les utilisations autonomes qui en decoulent | |
WO1992019732A1 (fr) | Oligonucleotides fermes, antisens et sens, et leurs applications | |
KR20160074368A (ko) | Utrn 발현을 조절하기 위한 조성물 및 방법 | |
CA2526893A1 (fr) | Inhibition de l'expression du gene de la huntingtine | |
US20070105808A1 (en) | Inhibition of histone deacetylase | |
JP2014028853A (ja) | 癌治療と幹細胞調節のための方法 | |
AU6718200A (en) | Inhibition of histone deacetylase | |
FR2699191A1 (fr) | Nouveaux vecteurs rétroviraux, lignées cellulaires les contenant, et leur utilisation dans le traitement des tumeurs. | |
WO2020168241A1 (fr) | Modulateurs de réactivation de x et leurs utilisations | |
Liao et al. | Pravastatin regulates host foreign-body reaction to polyetheretherketone implants via miR-29ab1-mediated SLIT3 upregulation | |
KR20170125954A (ko) | Tp53의 반접합성 손실을 지닌 암을 치료하는 방법 | |
FR2790757A1 (fr) | Oligonucleotides contenant une sequence antisens stabilises par une structure secondaire et compositions pharmaceutiques les contenant. | |
EP4352226A1 (fr) | Acides nucléiques peptidiques pour la régulation spatio-temporelle de la liaison de crispr-cas | |
KR20190083237A (ko) | 세포 유래 엑소좀을 포함하는 핵산 전달용 조성물, 키트, 및 이를 이용한 방법 | |
WO2003074060A2 (fr) | Combinaison chimiothérapie et antisens de la dna déméthylase | |
Rydh-Rinder et al. | Antinociceptive effects after intrathecal administration of phosphodiester-, 2′-O-allyl-, and C-5-propyne-modified antisense oligodeoxynucleotides targeting the NMDAR1 subunit in mouse | |
CA3237013A1 (fr) | Phytoecdysones et/ou derives de 20-hydroxyecdysone en combinaison avec un principe actif visant a restaurer l'expression smn pour leur utilisation dans le traitement de l'amyotrophie spinale | |
Gur et al. | Destination penis? Gene therapy as a possible treatment for erectile dysfunction | |
KR20110086850A (ko) | 종양의 치료에 적합한 올리고뉴클레오티드의 용량 | |
KR20220061920A (ko) | 인간 말초 혈액으로부터 유래된 엑소좀을 포함하는 유전자 전달체 및 이의 용도 | |
CN115397987A (zh) | 调节人l1反转录转座子rna的方法和用于其中的组合物 | |
WO2019164872A2 (fr) | Composition et procédé de ciblage de cellules tueuses naturelles en immunothérapie pour surmonter la suppression tumorale avec des nanoparticules de dioxyde de manganèse | |
DE10296800T5 (de) | Inhibitoren von Isoformen der DNA Methyltransferase | |
US20230374505A1 (en) | Human XIST Antisense Oligonucleotides for X Reactivation Therapy |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SC SD SE SG SK SL TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
CFP | Corrected version of a pamphlet front page | ||
CR1 | Correction of entry in section i |
Free format text: IN PCT GAZETTE 37/2003 ADD "DECLARATION UNDER RULE 4.17: - OF INVENTORSHIP (RULE 4.17(IV)) FOR US ONLY." |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2478124 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2003727568 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref document number: 2006009403 Country of ref document: US Kind code of ref document: A1 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 10506766 Country of ref document: US |
|
WWP | Wipo information: published in national office |
Ref document number: 2003727568 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 10506766 Country of ref document: US |
|
NENP | Non-entry into the national phase |
Ref country code: JP |
|
WWW | Wipo information: withdrawn in national office |
Country of ref document: JP |